EBMT
Owing to nearly 100% coverage by the health insurance system, the number of hematopoietic stem cell transplants (HSCT) has increased steadily in Japan. The current annual number of transplants is 3500, which consists of 1000 bone marrow or peripheral blood stem cell transplants from relatives, 900 bone marrow transplants from volunteer donors, 600 cord blood stem cell transplants and 1000 autologous bone marrow or peripheral blood stem cell transplants. These transplants are performed by more than 300 medical teams throughout the country. The Japan Marrow Donor Program (JMDP) was initiated by the Japan Bone Marrow Transplant Promotion Foundation in 1991 under the auspices of the Ministry of Health, Labor and Welfare, Japanese Red Cross, the district governments throughout the country, the related medical societies and many contributors/volunteers. Since then, JMDP has recruited 300 000 volunteer donors, has accepted 20 000 patients and has facilitated more than 8000 unrelated bone marrow transplants. The Japan Cord Blood Bank Network, which started in 1999 as the union of 11 local cord blood banks through the country, has collected 20 000 cord blood units and facilitated 4000 cord blood transplants up to now. Despite such progress, nevertheless, it is assumed that this number is only half of the potential annual requirement of HSCT in our country. To fulfill the need, international collaborations as well as domestic efforts are considered to be important for the future. As an international collaboration, JMDP has the official agreement for stem cell exchange with NMDP, BTCSCC, KMDP and CMDP and the cumulative exchange case numbers are 140 in and 145 out. In Japan, the study group of national grant from the Ministry of Health, Labor and Welfare has established the algorithm for the selection of unrelated donors according to HLA matching status, resulting in an increased opportunity to find feasible donors as well as a better outcome at unrelated bone marrow transplantation. Another domestic effort is the trial of the T cell non-depleted transplant from one haplotype-mismatched family donor who was suspected to be in the status of fetomaternal tolerance to the recipients. With tacrolimus as immune suppressant, the results of the trial showed that such a haplotype-mismatch transplant was feasible as a salvage transplant. To understand the status of HSCT and to know the future prospects, a highly qualified patients' and donors' registration system is essential. The Japan Society for Hematopoietic Cell Transplantation (JSHCT) has proposed a unified patient registration system 'TRUMP' in 2006 and so far has been successful in terms of the improved registration rate. APBMT decided to apply this system for Asia Blood and Marrow Transplant Registry (Asia BMT Registry) and the initial data were collected from eight out of 12 participating countries/regions. CIBMTR and EBMT also initiated the movement to create a common clinical record form last winter and called on APBMT to join them. It can be stated that the globalization of patient and donor registration for HSCT has become realistic and this could contribute to both the further improvement of patient outcomes and the further donor safety.
